Atlas Trials

Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

Clinical trial NCT05030675 · COMPLETED

Trial details

NCT number
NCT05030675
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Refractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
Start date
2021-08-13
Primary completion
2024-08-08
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.